A nearly three-month slide in the biotechnology market is prompting some venture capitalists to wonder if drug startups' sprint to the Nasdaq will slow to a crawl, Brian Gormley reports for Dow Jones VentureWire. Since late July, the Nasdaq Biotechnology Index has slipped nearly 23% amid a general market decline and the fallout from Turing Pharmaceuticals AG 's decision to hike the price of a rare-disease drug-a decision the company has since reversed.